Accéder au contenu
Merck
Toutes les photos(2)

Documents

L8793

Sigma-Aldrich

Anti-LC3A antibody produced in rabbit

~1 mg/mL, affinity isolated antibody, buffered aqueous solution

Synonyme(s) :

Anti-MAP1 light chain 3-like protein 1, Anti-MAP1A/1B light chain 3 A, Anti-MAP1A/MAP1B LC3 A, Anti-MAP1ALC3, Anti-MAP1BLC3, Anti-MAP1LC3A, Anti-Microtubule-associated protein 1 light chain 3 alpha

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

rabbit

Niveau de qualité

Conjugué

unconjugated

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

primary antibodies

Clone

polyclonal

Forme

buffered aqueous solution

Poids mol.

antigen 16-18 kDa

Espèces réactives

mouse, human, rat

Concentration

~1 mg/mL

Technique(s)

immunoprecipitation (IP): 5-10 μg using extracts of human U87 cells
western blot: 0.5-1 μg/mL using whole extracts of rat and mouse brain

Numéro d'accès UniProt

Conditions d'expédition

dry ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

Description générale

Microtubule-associated proteins 1A/1B light chain 3 or MAP1LC3 is a cellular protein that is involved in the formation of autophagosomes . MAP1LC3 genes have three known human isoforms, namely, MAP1LC3A, MAP1LC3B and MAP1LC3C. These isoforms have different responses to amino acid starvation and varied sub-cellular localization patterns . Anti-LC3A antibody reacts with human and rat LC3A-I (approx. 18 kDa) and LC3A-II (approx. 16 kDa) by immunoblotting and immunoprecipitation. The antibody is also specific for mouse LC3A-I (approx. 18 kDa). Specific cell treatment and/or long exposure may be required for the detection of mouse LC3A-II. The immunizing peptide specifically inhibits the detection of the LC3A bands by immunoblotting.

Spécificité

Anti-LC3A antibody recognizes human and rat microtubule-associated protein light chain 3-A (LC3A-I) and LC3A-II by immunoblotting and immunoprecipitation (~18 kDa and ~16 kDa, respectively) and mouse LC3A-I (~18 kDa).

Immunogène

Synthetic peptide corresponding to amino acids of human LC3A isoform α, conjugated to KLH via C-terminal cysteine residue. The corresponding sequence is identical in rat and mouse.

Application

Anti-LC3A antibody produced in rabbit has been used in
  • immunohistochemistry
  • immunostaining
  • western blotting

Actions biochimiques/physiologiques

Microtubule-associated protein light chain 3-I (LC3-I) is modified to a membrane-bound form, LC3-II (a LC3-phospholipid conjugate), by mammalian autophagy related 7 (Atg7) and Atg3, which are E1- and E2-like enzymes, respectively. The amount of LC3 II correlates with the extent of autophagosome formation. LC3A can also be as an autophagosomal marker.

Forme physique

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Stockage et stabilité

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Xuekai Zhang et al.
Alzheimer's research & therapy, 6(9), 78-78 (2015-01-27)
Many neurodegenerative diseases are characterised by accumulations of misfolded proteins that can colocalise with chaperone proteins (for example, heat shock protein 27 (HSP27)), which might act as modulators of protein aggregation. The role of HSP27 in the pathogenesis of neurodegenerative
Fangqin Yu et al.
Frontiers in oncology, 11, 638701-638701 (2021-05-04)
Thyroid cancer is one of the most common endocrine malignancies worldwide, and papillary thyroid cancer (PTC) is the most common pathologic type of thyroid cancer. SQSTM1/p62 activity mediates different biological functions. This study aimed to investigate the effect of SQSTM1/p62
Rowan Gurney et al.
Neuropathology : official journal of the Japanese Society of Neuropathology (2018-05-12)
A failure of protein degradation may underpin Lewy body disease (LBD) where α-synuclein is assimilated into the pathognomic Lewy bodies and Lewy neurites. We investigated histological alterations in lysosomes and autophagosomes in the substantia nigra (SN) and cingulate gyrus (CG)
João Cláudio Damasceno-Sá et al.
Memorias do Instituto Oswaldo Cruz, 116, e200417-e200417 (2021-03-18)
Toxoplasma gondii causes toxoplasmosis and is controlled by activated macrophages. However, infection of macrophages by tachyzoites induces TGF-β signaling (TGF-s) inhibiting nitric oxide (NO) production. NO inhibition may be a general escape mechanism of distinct T. gondii strains. To evaluate
Kaito Nihira et al.
The Journal of pathology, 234(2), 277-288 (2014-04-02)
The development of therapeutic resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs, ie erlotinib or gefitinib) has been the major clinical problem when treating lung adenocarcinoma patients with these agents. However, its mechanisms have not necessarily been well studied to this

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique